The purpose of T1com is to promote development and access to better treatments and ultimately a cure for type 1 diabetes, along with other related activities. The focus is on JDRF's research areas.
T1com is driven by sponsorships, partnerships, and consulting work as a social enterprise, ie. a business that is mission-driven rather than profit-maximizing.
T1com was founded in 2018 by Finn Stensbjerg Kristensen. His engagement in type 1 diabetes started when his son was diagnosed with the disease at the age of 15 months in 1998.
In 2003 he founded JDRF Denmark, was chairman of the board until February 2007, and CEO until December 2017. In 2019 he co-founded the charity Børnediabetes - Type 1 (Juvenile Diabetes - Type 1).
T1com ongoing projects
Convenience in Artificial Pancreas Therapy
Artificial pancreatic technology is a therapy with the potential to eliminate the risk of diabetes complications and give patients a normal life. A few systems are on the market, and more are on the way. However, a major obstacle to adoption of the systems among patients is the difficulties associated with using them. The Convenience in Artificial Pancreas Therapy project aims to support the development of technology to reduce these difficulties.
DiaUnion, Center for Diabetes, Autoimmunity and Prevention
Both Denmark and Sweden have strong research competencies within type 1 diabetes immunology and genetics. DiaUnion is working to create a transnational center that brings together the best forces from both countries in a joint research center. DiaUnion was supported with EUR 1MM in December 2019 and an additional EUR 1MM in October 2020, by EU Interreg and partners.
Hypo Rescue and Therapy
In type 1 diabetes, an antagonist is needed in situations where too much insulin has been dosed, leading to hypoglycemia and seizures. Hypoglycemia can be predicted by CGM, EEG, or a combination of the two, and liquid stable glucagon is the drug that can prevent or intervene in the condition. Hypo Rescue and Therapy activities aim to support the development of technologies to precisely and reliably predict hypoglycemic events, and automatically, safely, and conveniently deliver liquid, stable glucagon.
International Research Partnerships
There are great opportunities to build collaborations between researchers, industry, and foundations so that the research and development efforts are strengthened and resources extend further. The International Research Partnership activities work to initiate, facilitate, and promote collaboration between researchers, industry, and foundations worldwide.